Drugs / therapeutic autologous lymphocytes
last change Jun 2022 re-read 8 days ago

therapeutic autologous lymphocytes

Cell therapy targets CD19 via depletion

Developed for
cutaneous melanoma · breast cancer · metastatic melanoma · central nervous system neoplasm · lymphoma · leukemia · neuroblastoma · brain cancer
+20 more · cancer · cancer of unknown primary site · cervical cancer · chronic lymphocytic leukemia/small lymphocytic lymphoma · clear cell renal carcinoma · colorectal cancer · lung cancer · malignant glioma · malignant pancreatic neoplasm · MALT lymphoma · mantle cell lymphoma · melanoma · myelodysplastic syndrome · nodal marginal zone B-cell lymphoma · ovarian cancer · plasma cell myeloma · renal cell carcinoma · sarcoma · splenic marginal zone lymphoma · Waldenstrom macroglobulinemia
Investigated by
National Cancer Institute (NCI) · Fred Hutchinson Cancer Center · Barbara Ann Karmanos Cancer Institute · City of Hope Medical Center · Roger Williams Medical Center · Beth Israel Deaconess Medical Center
+9 more · Dana-Farber Cancer Institute · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium · Gary Archer Ph.D. · Hoag Memorial Hospital Presbyterian · Milton S. Hershey Medical Center · National Institutes of Health Clinical Center (CC) · Stanford University · University of Maryland Greenebaum Cancer Center · University of Maryland, Baltimore

Trials 31

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 119 trials
Phase 1 NCT01943188 May 2014 → Mar 2016 clear cell renal carcinoma Stanford University Terminated No outcome recorded
Phase 1 NCT01339663 Mar → Dec 2012 metastatic melanoma Fred Hutchinson Cancer Center Completed No outcome recorded
Phase 1 NCT01106235 Apr 2010 → Nov 2011 metastatic melanoma Fred Hutchinson Cancer Center Terminated No outcome recorded
Phase 1 NCT00621452 Aug 2007 → Jan 2014 MALT lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma +2 Fred Hutchinson Cancer Center Completed No outcome recorded
Phase 1 NCT00512889 Aug 2007 → Feb 2011 cutaneous melanoma Dana-Farber Cancer Institute Completed No outcome recorded
Phase 1 NCT00438984 Dec 2006 → Jan 2011 metastatic melanoma Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Completed No outcome recorded
Phase 1 NCT00639639 Feb 2006 → Apr 2017 malignant glioma Gary Archer Ph.D. Completed No outcome recorded
Phase 1 NCT00101309 Nov 2004 → Nov 2007 neuroblastoma, sarcoma Milton S. Hershey Medical Center Unknown No outcome recorded
Phase 1 NCT00182650 Jun 2004 → Mar 2008 lymphoma City of Hope Medical Center Completed No outcome recorded
Phase 1 NCT00085462 May 2004 → May 2007 cutaneous melanoma National Institutes of Health Clinical Center (CC) Completed No outcome recorded
Phase 1/24 trials
Phase 1/2 NCT00945269 Jul 2009 → Jan 2011 melanoma Fred Hutchinson Cancer Center Terminated No outcome recorded
Phase 1/2 NCT00553306 Sep 2007 → Aug 2010 metastatic melanoma Fred Hutchinson Cancer Center Completed No outcome recorded
Phase 1/2 NCT00046852 Dec 2001 → Nov 2004 infectious disease, plasma cell myeloma University of Maryland, Baltimore Completed No outcome recorded
Phase 1/2 NCT00022230 Jan 2000 → Jan 2007 breast cancer Roger Williams Medical Center Withdrawn No outcome recorded
Phase 28 trials
Phase 2 NCT00020722 Aug 2007 → Mar 2013 breast cancer Barbara Ann Karmanos Cancer Institute Terminated No outcome recorded Stop: Business
Phase 2 NCT00079144 Jan 2004 → Aug 2005 cutaneous melanoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT00331526 Feb 1999 → Dec 2008 central nervous system neoplasm Hoag Memorial Hospital Presbyterian Completed No outcome recorded
Phase 2 NCT00014573 Aug 1998 → Oct 2004 brain cancer Barbara Ann Karmanos Cancer Institute Completed No outcome recorded
Phase 2 NCT00004022 Jun 1997 → Jan 2004 cutaneous melanoma Barbara Ann Karmanos Cancer Institute Completed No outcome recorded
Phase 2 NCT00004024 Jun 1997 → Jan 2004 central nervous system neoplasm Barbara Ann Karmanos Cancer Institute Completed No outcome recorded
Phase 2 NCT00019084 Feb 1996 → May 2003 breast cancer, cervical cancer, colorectal cancer, lung cancer +2 National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT00002589 Jul 1994 → ? renal cell carcinoma National Cancer Institute (NCI) Unknown No outcome recorded
Comparator or background therapy2 trials
Phase 1 NCT00003567 Background May 1999 → Jan 2007 cancer of unknown primary site, central nervous system neoplasm, lymphoma Case Comprehensive Cancer Center Terminated No outcome recorded Stop: Enrollment
Phase 2 NCT00303836 Background Nov 2005 → Jan 2007 metastatic melanoma National Cancer Institute (NCI) Terminated No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 34 sources stand behind the page.

FieldValueCited text
Known as therapeutic autologous lymphocytes ClinicalTrials.gov intervention name — accepted as the source's own label NCT00303836 ↗
32

NCT00006480 ↗

NCT00730613 ↗

NCT00331526 ↗

NCT01106235 ↗

NCT00182650 ↗

NCT00107354 ↗

NCT00002589 ↗

NCT00027807 ↗

NCT00019357 ↗

NCT00079144 ↗

Show 22 more sources

Known as autologous lymphocyte transfer (ALT) “CMV-autologous lymphocyte transfer (ALT)” NCT00639639 ↗
Known as Autologous peptide-specific activated lymphocytes “Autologous peptide-specific activated lymphocytes (PAL), previously harvested from the patient following vaccination on a different protocol, are expanded and reinfused intravenously” NCT00019357 ↗
Known as PAL “Autologous peptide-specific activated lymphocytes (PAL), previously harvested from the patient following vaccination on a different protocol, are expanded and reinfused intravenously” NCT00019357 ↗
Action Deplete “Armed T cells aggregated and specifically killed HER2/neu(+) breast cancer cells.” PMID 11359672 ↗ Apr 2001
Modality Cell therapy “the autologous lymphocytes are reinfused over at least 30 minutes” NCT00002589 ↗
Route Intravenous “The activated T lymphocytes are infused IV over 1-6 hours” NCT00004022 ↗
Target CD19 “CD3-positive cytotoxic T lymphocytes (CTLs) are isolated and genetically modified to express a CD19-specific chimeric immunoreceptor and the HyTK fusion protein, and are then...” NCT00182650 ↗